Articles On Starpharma Holdings (ASX:SPL)

Starpharma (ASX:SPL) has announced the appointment of Justin Cahill as its chief financial officer and company secretary.

What a solid day it’s been for the ASX today, with the benchmark maintaining a strong run past +1.1% for the afternoon, to finish at +1.18% when the bell finally rang, and the old ladies running the ASX called “pencils down” and everyone go...

The S&P/ASX 200 Index (ASX: XJO) has followed Wall Street’s lead and is on course to end the week in the red. At the time of writing, the benchmark index is down 0.8% to 7,094.3 points. Four ASX shares that have not let that hold th...

Biopharmaceutical company Starpharma (SPL) receives a $7.1 million research and development tax incentive refund The tax offset relates to SPL’s Australian and global expenses over the 2022 financial year Starpharma CEO Jackie Fairley...

After yesterday’s pre-Chrimbo spend-up, SPI Futures are down 66 points (-0.38%) this morning, threatening to wipe out yesterday’s 41-point gain. That’s on the back of some good/bad, depends-on-your-worldview news out of the US that data con...

The preliminary results of the clinical trial involving AstraZeneca's AZD0466 and the drug delivery platform developed by Starpharma (ASX:SPL) have been presented at the 2022 American Society of Hematology annual meeting.

Highlights The ASX 200 benchmark index closed in the green today (December 14), gaining 48.00 points, or 0.67%, to end at 7,251.30 points. Over the last five days, the index has gained 0.30%, but is down 2.60% for the last year to date...

Starpharma (SPL) registers its nasal spray product VIRALEZE in Indonesia after gaining marketing authorisationThe company says Indonesia represents an “exciting market opportunity” as its the largest and most populated country in Southeast...

Clarity Pharma announced positive results from Phase 1 trial Starpharma brings VIRALEZE to Indonesia Race Oncology has a new CEO   Clarity Pharma (ASX:CU6) announced that its diagnostic 64Cu SAR-bisPSMA Phase I trial PROPELLER has met all...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain. At the time of writing, the benchmark index is up 0.2% to 7,196.9 points. Four ASX shares that are climbing more than most today are listed belo...

There’s been plenty of insider buying going on among ASX shares lately, and many of the targets are trading at, or around, 52-week lows. That suggests those in the know believe their company is trading at attractive prices. So much so, t...

Starpharma (SPL) spent the September quarter progressing its DEP technology and signing a new research agreementIn mid-August, the company signed a new DEP research agreement with MSD to design and synthesise a number of DEP dendrimer conju...

Starpharma (SPL) signs an agreement with Hengan Pharmacare for the sale and distribution of its nasal spray product, VIRALEZE, in Hong Kong and MacauThe agreement will last for an initial two years and will see Starpharma supply VIRALEZE to...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

The ASX 200 is vacillating Small caps are down over 1.3% Demetallica is a great name and it’s up 40% on takeover talk   The benchmark ASX 200 is flat as on Monday. The ASX Emerging Companies (XEC) index has lost 1.3%. REITs and Gold are h...

Starpharma (SPL) presents promising anti-tumour activity data in prostate cancer at the European Society of Medical Oncology (ESMO) Congress in ParisThe data shows DEP cabazitaxel has a number of key advantages which included superior effic...

Starpharma (ASX:SPL) has been announced as the winner of the ‘Most Significant Commercial Outcome’ award following the completion of a Biomedical Translation Bridge program backed by the federal government’s Medical Research Future...

Starpharma (SPL) signs a new DEP research agreement with MSD, the trade name of Merck Sharp & Dohme Under this agreement, Starpharma will design and synthesise a number of DEP dendrimer conjugates for MSD to test and characterise This...

Starpharma (ASX:SPL) has announced a new research agreement with MSD under which the Australian company will design and synthesise a number of DEP dendrimer conjugates and provide them to the US-based company for testing and charact...

Starpharma (SPL) confirms its VIRALEZE antiviral nasal spray demonstrates a high level of protection against the infectious SARS-CoV-2 Omicron variant In the study, all the test animals were treated with VIRALEZE in vivo in a humanised mou...

After a brutal start to this Friday’s trading session, the All Ordinaries Index (ASX: XAO) has recovered somewhat. At the time of writing, the All Ords is still down by 0.72% at around 6,800 points after going as low as 6,733 points this m...

Starpharma (SPL) relaunches its VIRALEZE nasal spray with LloydsPharmacy in the United Kingdom VIRALEZE will be supplied exclusively to LloydsPharmacy under its existing sales and distribution agreements LloydsPharmacy is one of the larges...

Cann Group’s Mildura facility has been granted GMP licence Paradigm receives patent application acceptance by IP Australia Starpharma to relaunch VIRALZEE with LloydsPharmacy in the UK Cannabis company Cann Group (ASX:CAN) rose 17% this m...

The Starpharma Holdings Ltd (ASX: SPL) share price has jumped out of the gates and is trading higher on Thursday. At the time of writing, investors are bidding Starpharma 5% higher to 70 cents apiece. Support comes following a company a...

Starpharma (ASX:SPL) has announced that VIRALEZE nasal spray has been relaunched by LloydsPharmacy in the UK.

Starpharma (ASX:SPL) has signed an expanded DEP research agreement with Genentech, a member of the Roche Group, to evaluate additional DEP drug conjugates.

ShareCafeLunch Report: 27 June, 2022 by Lauren Evans   The Australian sharemarket has rallied this morning with all eleven sectors in the green. Materials are leading the pack, up 2.6 per cent, followed by energy, up 2.4 per cent. The secto...

Starpharma (SPL) expands its research agreement with Genentech for its drug delivery technology, DEP The initial agreement was signed in December 2021 and involves Starpharma designing and synthesising dendrimer-based drug conjugates for G...

When is a medicine actually a medical device? The question has been more than academic for Starpharma (ASX:SPL), which ran into a spot of bother with Australia’s Therapeutic Goods Administration (TGA) as to what category its anti-viral nasa...

Starpharma (ASX:SPL) says SPL7013, the antiviral agent in VIRALEZE nasal spray, achieved 95 per cent and 99.7 per cent reduction in viral infectivity against two significant types of influenza virus, A and B, respectively, in viruci...

Starpharma’s (SPL) antiviral agent achieves up to 99.7 per cent reduction in viral activity against two types of influenzas virus The company’s antiviral agent in its VIRALEZE nasal spray achieved a 95 per cent and 99.7 per cent reduction...

ShareCafeWebinar Recap – MX1, SPL, MAP, RFL & RAP Catch up on the full webinar with presentations from Micro-X (ASX: MX1), Starpharma (ASX: SPL), Microba Life Sciences (ASX: MAP), RLF AgTech (ASX: RFL) & ResApp (ASX: RAP) Webinar R...

ShareCafeStarpharma (ASX: SPL) – Webinar Presentation Dr Jackie Fairley – CEO – Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical,...

Starpharma (SPL) will relaunch antiviral nasal spray VIRALEZE in the UK following the resolution of queries raised by the UK Medicines and Healthcare products Regulatory Agency (MHRA) In June 2021, Starpharma’s UK retail partner LloydsPhar...

Cann Group gets the OK in the UK for its CBD food supplements Starpharma to relaunch VIRALEZE in the UK Creso expands to LATAM Cann Group gets OK in the UK Cannabis company Cann Group (ASX:CAN) has received the green light from the UK FSA...

The Starpharma Holdings Limited (ASX: SPL) share price is up 6% following a company announcement to the market this morning. Starpharma has announced it will relaunch its VIRALEZE antiviral nasal spray in the UK after resolving issues rai...

Highlights Incannex’s preliminary assessment of proof-of-concept trial data has indicated efficacy and good safety characteristics of IHL-42X. The data highlighted substantial reduction in AHI, meeting the expectations. Average of low...

Plenty of ASX healthcare shares fell to 52-week lows today. The industry has not been immune to the ASX share market selloff. There is ongoing volatility with investors keeping an on the Russian conflict with Ukraine, the sanctions and the...

Highlights The ASX 200 snapped its 5 day winning streak today, was down 0.6% to close at 7110. Fears over Russian shelling at Europe's biggest nuclear plant in Ukraine weighed on the global market sentiment today. Investors globally r...

Shares in Starpharma Holdings Limited (ASX: SPH) are on the move today after the company released a market sensitive announcement. At the time of writing, the Starpharma share price is down 7.87% at 82 cents. The announcement relates to a...

Highlights The ASX 200 plunged 0.59% in the first 15 minutes of opening trade. Wall Street's main indices continued their volatile session on Thursday, ending in the red. The IT sector is leading the fall with a 2.62% cut. The Aus...

Starpharma (ASX:SPL) has announced that its Australian developed VIRALEZE antiviral nasal spray achieved the maximum possible virucidal effect against the highly transmissible Omicron variant of SARS-CoV-2. 

The antiviral agent in VIRALEZE antiviral nasal spray, SPL7013, achieved >99.5% reduction of virus infectivity (the maximal possible reduction) against the highly contagious Omicron variant of SARS-CoV-2 SPL7013 showed potent antivir...

Starpharma’s (SPL) antiviral nasal spray achieves a greater than 99.5 per cent reduction of virus infectivity against the Omicron variant of SARS-CoV-2 The antiviral agent in VIRALEZE reached the maximum possible reduction of virus infecti...

Shares in Starpharma Holdings Ltd (ASX: SPL) are cruising higher today and now trade 4% in the green at 92 cents apiece. Investors are responding positively to a company announcement regarding its lead drug candidate Viraleze in the fight...

Australian company Starpharma (ASX:SPL) has announced a strong result for the six months to the end of 2021 headlined by strong revenue growth and new commercialisation agreements.

The Starpharma Holdings Ltd (ASX: SPH) share priced closed in the red on Monday after the company released its interim report and financial results for the half-year ended 31 December 2021. Starpharma shares finished the day 5% down at 98....

The ASX 200 Health Index (XHJ) has fallen by 1.26% at the time of writing, compared to the broader index which is down by 0.12%. Medical device company OncoSil Medical (ASX:OSL) surged as high as 25% up today, after its device was granted a...

Starpharma (SPL) signs a deal for its antiviral nasal spray to be available for purchase across nine new countries Through a five-year sales and distribution agreement, VIRALEZE will be available for purchase in Saudi Arabia and eight othe...

Starpharma (SPL) records $1.8 million in receipts from customers for the December quarter, primarily due to the launch of VIRALEZE in Vietnam VIRALEZE launched in Vietnam in December with the product to be distributed by Truong Bao Land In...